# Novel Experimental COVID-19 Therapies Affecting Host Response

> **NCT04924660** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sean Collins** · enrollment: 1060 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection
- Coronavirus Infection

## Interventions

- **DRUG:** TXA127
- **DRUG:** TRV027
- **DRUG:** Placebo
- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT04924660
- **Lead sponsor:** Sean Collins
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2023-10-25
- **Final completion:** 2023-12-31
- **Target enrollment:** 1060 (ACTUAL)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04924660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04924660, "Novel Experimental COVID-19 Therapies Affecting Host Response". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04924660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*